Abeona Therapeutics CCO Madhav sells $25,272 in stock

Vasanthavada Madhav, Chief Commercial Officer at Abeona Therapeutics Inc., divested 4,902 shares of the company's stock on September 29, 2026. The shares were sold for a total of $25,272, with an average price of $5.1556 per share. This transaction was executed to settle tax liabilities resulting from the vesting of restricted stock awards.

During the same week, the stock price of Abeona Therapeutics had dropped by 6.7%, reaching $5.16, which was near its 52-week low of $4.00. Despite this decline, analysts maintain that the stock is undervalued, with a projected Fair Value of $5.96. Abeona Therapeutics has been experiencing fluctuations in its financial performance.

While the second-quarter revenue from its lead therapy, ZEVASKYN, grew by 31% to $11.4 million, it was still below the anticipated $12.24 million. The company reported a net loss of $20.2 million, or $0.35 per share, as it continues to expand its commercial presence and treatment center network. Recently, the FDA granted approval to a gene therapy, FAYUVI, developed by Abeona Therapeutics and co-owned by Ultragenyx, for the treatment of Sanfilippo syndrome type A. This approval has prompted analysts to upgrade Abeona Therapeutics, with H.C.

Wainwright maintaining a Buy rating and a $20 price target, and Cantor Fitzgerald raising its price target to $30 with an Overweight rating. Furthermore, Roth/MKM has also initiated coverage on Abeona Therapeutics, assigning it a Buy rating and a $17 price target, acknowledging the promising outlook for the company's ZEVASKYN therapy.